Imugene wins ASH poster slot for azer-cel Phase 1b data
Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has announced that an abstract on azer-cel has been selected for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held from 12-15 December 2026 in New Orleans, Louisiana.
Acceptance followed ASH’s rigorous peer-review process, which the company says reflects the scientific merit and clinical interest in azer-cel’s Phase 1b clinical trial data. For investors, the selection places the company’s lead asset before an international audience of haematology experts at a global venue.
The ASH poster follows an earlier oral slot at ASCO earlier in 2026, where azer-cel was picked from more than 8,500 submitted abstracts.
When big ASX news breaks, our subscribers know first
Poster details at a glance
The abstract has been placed within a dedicated poster session at the meeting. The table below sets out the key details.
| Detail | Information |
|---|---|
| Abstract title | “Safety and efficacy of azer-cel, an allogeneic CD19-directed CAR T-cell therapy, with concomitant Bruton tyrosine kinase inhibitor therapy in patients with relapsed/refractory B-cell malignancies” |
| Session | “Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II” |
| Date and time | 13 December 2026, 6:00pm – 8:00pm US Central Standard Time |
| Venue | New Orleans Ernest N. Morial Convention Center, Louisiana |
ASH describes its Annual Meeting as the world’s premier event for advancing hematology research and science, attracting over 30,000 global clinicians, researchers and industry leaders.
Paul Hopper, Executive Chairman, Imugene
“We are eager to share emerging data from our Phase 1b study in non-Hodgkin lymphomas and highlight the potential for azer-cel when combined with BTK inhibitors in patients who have previously progressed on prior BTKi therapy…”
Mr Hopper added that presenting at the congress allows the company to engage directly with international experts.
What azer-cel is and why combining it with BTK inhibitors matters
The abstract focuses on azer-cel used alongside a class of existing treatments. A short primer on the key terms:
- Azer-cel (azercabtagene zapreleucel): an off-the-shelf (allogeneic) CAR T cell therapy that targets CD19 in blood cancers.
- Allogeneic: the cells are not made from each individual patient.
- BTK inhibitors: existing treatments, and Imugene is focused on developing azer-cel for patients with B-cell cancers whose disease has progressed on existing treatments, including CAR T and BTK inhibitors.
Mr Hopper said the company sees potential for its allogeneic CAR T platform, particularly in patients with limited treatment options.
Early readouts from the BTKi combination cohort have already reported complete and partial responses in patients who relapsed on prior BTK inhibitor therapy, alongside a combined 75% response rate across 55 Phase 1b patients.
What happens next for Imugene at ASH
Three items frame the company’s near-term calendar at the meeting:
- Poster presentation: 13 December 2026, 6:00pm – 8:00pm US Central Standard Time, at the New Orleans Ernest N. Morial Convention Center, within the Poster II session.
- Poster release: following its release, the poster will be available on Imugene’s website at https://imugene.com/investors/conference-presentations/.
- ASH Annual Meeting: runs 12-15 December 2026 in New Orleans, Louisiana.
For investors, the presentation is primarily a visibility event, giving Imugene a platform to present its Phase 1b azer-cel data to the international haematology community.
Want to Explore Imugene’s Azer-Cel Phase 1b Progress?
Imugene’s azer-cel, an allogeneic CD19-directed CAR T-cell therapy, is heading to the ASH Annual Meeting in December 2026 following its earlier selection for an oral slot at ASCO. With a combined 75% response rate reported across 55 Phase 1b patients, the program is attracting growing attention from the global haematology community.
Investors wanting the full detail can view Imugene’s latest ASX announcements for the company’s clinical updates and milestones. Stay informed as azer-cel moves towards its poster presentation in New Orleans.